Similar Items: Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
- In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
- Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
- Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat Pseudomonas aeruginosa clinical isolates
- P74 Addition of probenecid to β-lactam antibiotics in the treatment of skin and soft tissue infections: a systematic review
- Selected β-lactam resistance in selected species of gram-negative bacteria
- In vitro activity of eravacycline and comparator agents against Gram-negative and Gram-positive bacteria: results from China Antimicrobial Surveillance Network between 2017 and 2019